Pfizer touts atirmociclib success
But this comes in second-line breast cancer, a use the group isn’t pursuing.
Roche flunks its first-line degrader test
Persevera is a bust, but Roche hasn’t given up on the front line.
SABCS 2025 – Carrick sees a way forward in CDK7
The group will start a pivotal trial of samuraciclib following promising second-line results.
SABCS 2025 – Roche mounts its early breast cancer challenge
Giredestrant’s adjuvant benefit looks similar to that of Kisqali and Verzenio.
ESMO 2025 – Roche sticks it to its SERD rivals
But it will be up to regulators to decide if giredestrant has done enough for an all-comers label.
ESMO 2025 – Enhertu’s perioperative Destiny beckons
Enhertu improves outcomes in (neo)adjuvant breast cancer, but toxicity resurfaces.
ESMO 2025 preview – Merck hopes for Daiichi redemption
The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.
